Long-term outcome in patients with symptomatic low-grade oligodendrogliomatous tumors treated by cytotoxic agents;Effets à long terme de la chimiothérapie chez 7 patients présentant un gliome de bas grade symptomatique

Revue Neurologique

Volumn 162, Issue 11, 2006, Pages 1069-1075

  Catenoix, H ^a   Honnorat, J ^a   Cartalat Carel, S ^a   Chapuis, F ^b   Nighoghossian, N ^a   Trouillas, P ^a  

^a HÔPITAL NEUROLOGIQUE   (France)

^b HOSPICES CIVILS DE LYON   (France)

Author keywords

Large tumoral volume; Long term follow up; Low grade oligodendroglioma; PCV; Progression

Indexed keywords

CYTOTOXIC AGENT; LOMUSTINE; PROCARBAZINE; VINCRISTINE;

ADULT; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; LONG TERM CARE; MALE; NEUROLOGIC DISEASE; OLIGODENDROGLIOMA; QUALITY OF LIFE; RADIOLOGY; SYMPTOM; TREATMENT OUTCOME; TREATMENT RESPONSE; TUMOR VOLUME;

EID: 33750693687     PISSN: 00353787     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0035-3787(06)75119-0     Document Type: Article

References (33)

1. BISHOP M, DE LA MONTE SM. (1989). Dual lineage of astrocytomas. Am J Pathol, 135: 517-527.
2. BRADA M, VIVIERS L, ABSON C et al. (2003). Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol, 14: 1715-1721.
3. BROWN PD, BUCKNER JC, O'FALLON JR et al. (2003). Effects of radiotherapy on cognitive function in patients with low-grade glioma measured by the folstein mini-mental test examination. J Clin Oncol, 21: 2519-2524.
4. BUCKNER J, GESME D, O'FALLON J et al. (2003). Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patient with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol, 21: 251-255.
5. CAIRNCROSS JG, MAC DONALD DR. (1988). Successful chemotherapy for recurrent malignant oligodendroglioma. Ann Neurol, 23: 360-364.
6. CAIRNCROSS G, MACDONALD D, LUDWIN S et al. (1994). Chemotherapy for anaplastic oligodendroglioma. J Clin Oncol, 12: 2013-2021.
7. CAIRNCROSS JG, UEKI K, ZLATESCU MC et al. (1998). Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst, 90: 1473-1479.
8. CAIRNCROSS JG. (2000). Understanding low-grade glioma. Neurology, 54: 1402-1403.
9. CELLI P, NOFRONE I, PALMA L, CANTORE G, FORTUNA A. (1994). Cerebral oligodendroglioma: prognostic factors and life history. Neurosurg, 35: 1018-1035.
10. CHAHLAVI A, KANNER A, PEEREBOOM D, STAUGAITIS SM, ELSON P, BARNETT G. (2003). Impact of chromosome 1p status in response of oligodendroglioma to temozolomide: Preliminary results. J Neurooncol, 61: 267-273.
11. DUFFAU H, TAILLANDER L, CAPELLE L. (2006). Radical surgery after chemotherapy: a new therapeutic strategy to envision in grade II glioma. J Neuroonco, Sous presse.
12. HENDERSON KH, SHAW EG. (2001). Randomized trials of radiation therapy in adult low-grade gliomas Semin Radiat Oncol, 11: 145-151.
13. HONNORAT J. (2004). Quand et comment traiter un «gliome de bas grade»? Rev Neurol (Paris), 160 : 507-509.
14. HOANG-XUAN K, CAPELLE L, KUJAS M et al. (2004). Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol, 22: 3133-3138.
15. IDBAIH A, MARIE Y, PIERRON G et al. (2005). Two types of chromosome 1p losses with opposite significance in gliomas. J Clin Oncol, 22: 3133-3138.
16. KARIM AB, MAAT B, HATLEVOLL R et al. (1996). A randomized trial on dose-response in radiation therapy of low-grade cerebral gliomas: European organization for research and treatment of cancer (EORTC). Int J Radiat Oncol Biol Phys, 36: 549-556.
17. KARIM AB, AFRA D, CORNU P et al. (2002). Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research Council study BRO4: an interim analysis. Int J radiat Oncol Biol Phys, 52: 316-324.
18. KRAUS JA, KOOPMANN J, KASKEL P et al. (1995). Shared allelic losses on chromosomes 1p and 19q suggest a common origin of oligodendroglioma and oligoastrocytoma. J Neuropathol Exp Neurol, 54: 91-95.
19. LEBRUN C, FONTAINE D, RAMAIOLI A et al. (2004a). Long-term outcome of oligodendrogliomas. Neurology, 62: 1783-1787.
20. LEBRUN C, FONTAINE D, VANDENBOS F et al. (2004b). Chimiothérapie néoadjuvante dans les astrocytomes fibrillaires de grade II symptomatiques non opérables de l'adulte. Rev Neurol (Paris), 160: 533-537.
21. MASON WP, KROL GS, DEANGELIS LM. (1996). Low-grade oligodendroglioma responds to chemotherapy. Neurology, 46: 203-207.
22. OLSON JD, RIEDEL E, DEANGELIS LM. (2000). Long-term outcome of low-grade oligodendroglioma and mixed glioma. Neurology, 54: 1442-1448.
23. PACE A, VIDIRI A, GALIE E, CAROSI M et al. (2003). Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol, 14: 1722-1726.
24. PETERSON K, CAIRNCROSS J. (1996). Oligodendroglioma. Cancer Investigation, 14: 243-251.
25. QUINN JA, REARDON DA, FRIEDMAN AH. (2003). Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol, 21: 646-651.
26. SHAW E, ARUSELL R, SCHEITHAUER B et al. (2002). Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade gliomas: initial report of a north central cancer treatment group/radiation therapy oncology group/Eastern cooperative oncology group study. J Clin Oncol, 20: 2267-2276.
27. SOFFIETTI R, RUDA R, BRADAC GB, SCHIFFER D. (1998). PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery, 43: 1066-1073.
28. SOFFIETTI R, RUDA R, BORGOGNONE M, SCHIFFER D. (1999). Chemetherapy with PCV for low grade nonenhancing oligodendrogliomas ans oligoastrocytomas. Neurology, 52: 423-, (abstr POS-073, suppl 2).
29. STEIGER HJ, MARKWALDER RV, SEILER RW, EBELING U, REULEN HJ. (1990). Early prognosis of supratentoriel grade II astrocytomas in adult patients after resection or stereotactic biopsy. An analysis of 50 cases operated on between 1984 and 1988. Acta Neurochir, 106: 99-105.
30. STEGE EM, KROS JM, DE BRUIN HG et al. (2005). Successful treatment of low-grade oligodendroglial tumors with a chemotherapy regimen of procarbazine, lomustine, and vincristine. Cancer, 15: 802-809.
31. VAN DEN BENT MJ, TAPHOORN MJB, BRANDES AA et al. (2003). Phase II study of first-line chemotherapy with temozolomide in recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group study 26971. J Clin Oncol, 21: 2525-2528.
32. VAN DEN BENT MJ, AFRA D, DE WITTE O et al. (2005). Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet, 17: 985-990.
33. WESSELS H, WEBER W, RAVEN G, RAMAEKERS F, HOPMAN A, TWIJNSTRA A. (2003). Supratentorial grade II astrocytoma: biological features and clinical course. Lancet Neurol, 2: 395-403.